Everolimus: targeted therapy on the horizon for the treatment of breast cancer

CM Barnett - … : The Journal of Human Pharmacology and Drug …, 2012 - Wiley Online Library
The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3‐kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …
被引用次数：46 相关文章

Everolimus: targeted therapy on the horizon for the treatment of breast cancer.

CM Barnett - Pharmacotherapy, 2012 - europepmc.org
The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3-kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …

Everolimus: targeted therapy on the horizon for the treatment of breast cancer

CM Barnett - Pharmacotherapy, 2012 - pubmed.ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3-kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …

[引用][C] Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

CM Barnett - … : The Journal of Human Pharmacology and Drug …, 2012 - cir.nii.ac.jp
Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

[引用][C] Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

CM BARNETT - Pharmacotherapy, 2012 - pascal-francis.inist.fr
Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …

[引用][C] Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

CM BARNETT - Pharmacotherapy, 2012 - Pharmacotherapy